Citadel Advisors’s Korro Bio KRRO Stock Holding History

Citadel Advisors’s Portfolio KRRO Stock Details KRRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$163K	Sell	12,400 -156,300	-93%	-$1.94M	﹤0.01%	12270
2026 Q1	$1.91M	Sell	168,700 -110,300	-40%	-$1.21M	﹤0.01%	6155
2025 Q4	$2.23M	Buy	+279,000	New	+$6.52M	﹤0.01%	5703
2023 Q3	–	Sell	-78	Closed	-$1.35K	–	14730
2023 Q2	$1.35K	Sell	78 -1,226	-94%	-$23.8K	﹤0.01%	13947
2023 Q1	$32.8K	Buy	1,304 +1,244	+2,073%	+$142K	﹤0.01%	12641
2022 Q4	$11.6K	Buy	+60	New	+$6.17K	﹤0.01%	13563
2021 Q4	–	Sell	-432	Closed	-$153K	–	14325
2021 Q3	$153K	Sell	432 -588	-58%	-$231K	﹤0.01%	12358
2021 Q2	$508K	Sell	1,020 -3,210	-76%	-$1.57M	﹤0.01%	10028
2021 Q1	$2.01M	Buy	4,230 +3,998	+1,723%	+$7.77M	﹤0.01%	6371
2020 Q4	$409K	Buy	+232	New	+$306K	﹤0.01%	8516

Other funds holding KRRO

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Citadel Advisors's KRRO Position: Q2 2026 in Review

Citadel Advisors increased its Korro Bio (KRRO) stake by 31% in Q2 2026, buying an estimated $118K and bringing the position to 40,390 shares worth $532K. The position accounts for ﹤0.01% of the portfolio, ranked #9707.

Citadel Advisors first reported a position in KRRO in Q4 2019 and has held it in 23 quarters since. The position peaked at $46.4M in Q1 2024. 106 funds tracked by Wall St. Rank hold KRRO as of Q2 2026.

Citadel Advisors held 40,390 shares of Korro Bio worth $532K as of Q2 2026.
Citadel Advisors bought 9,476 Korro Bio shares in Q2 2026, an estimated $118K.
Korro Bio made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #9707 holding.
Citadel Advisors first reported a position in Korro Bio in Q4 2019 and has held it in 23 quarters since.
Citadel Advisors's Korro Bio position peaked at $46.4M in Q1 2024.
106 funds tracked by Wall St. Rank held Korro Bio as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.